AzTrials
AzTrials

Alcohol AbuseDEPREV_Phase_2NCT05125783

Influence of Alcohol Marketing Stimuli in Adults With Regular Alcohol Consumption

An observational study of Alcohol Abuse, run by University Hospital, Brest at 7 sites in France.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

Alcohol use is the second leading cause of preventable death after smoking. The Evin law was built in 1991 with the goal of reducing exposure to alcohol marketing among the youngest. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Alcohol Abuse
What is being tested?
questionnaire
How many people
287 participants
Where
7 sitesFrance
Study dates
7 Feb 2022to 7 Dec 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Adult, Older adult

Study population: Patients over 18 years of age followed in the addictology services participating in the study with moderate or severe alcohol use disorders.

Who may be able to join

  • Patient over 18 years of age
  • Patient with moderate to severe alcohol use disorders (beyond 3 out of 11 criteria on the DSM-5 scale)
  • Non-opposition of the patient

Who cannot join

  • Minor patient
  • Patient who has already participated in phase 1 of the project
  • Non-comprehension of the written French language
  • Refusal to participate in the study
  • Patient of legal age, deprived of liberty by a judicial or administrative decision or unable to express their consent

Trial locations and contacts

7 sites in 1 country.

7 sites in 1 country

France7 sites

  • Les Apsyades

    Bouguenais, 44344

  • François-Néri VANDERMERSCH

    Bouguenais

  • Morgane GUILLOU-LANDREAT

    Brest, 29609

  • Jean-Pierre SIMSON

    Brest

  • Pascale ROZEC

    Landerneau

  • Benoit SCHRECK

    Nantes

  • Hôpital Paul Brousse

    Villejuif, 94804

Other trials in France

About this study

Official title: Multifactorial Analysis of the Influence of Alcohol Marketing Stimuli in Adults With Regular Alcohol Consumption on the Perception of Alcohol Risks and According to Types of Use and Individual Vulnerabilities

Alcohol use is the second leading cause of preventable death after smoking. The Evin law was built in 1991 with the goal of reducing exposure to alcohol marketing among the youngest. But this law is currently extremely weakened, and in a press release of February 26, 2018, the French Society of Alcoology is alarmed by these developments.

Studies on the impact of alcohol marketing focus for the most part on young adolescents and the links between marketing exposure and alcohol initiation. But beyond these links, little work has been done on the impact of alcohol marketing on vulnerable subjects with regular alcohol consumption. Alcohol consumption is one of the very first causes of hospitalization in France. The damage is often limited to the notion of risks of dependence, but it can appear as soon as consumption of 1 standard unit/day and mainly concerns the 45-64 year olds. To investigator knowledge, there are no studies on the impact of alcohol marketing carried out among regular alcohol users with moderate or severe alcohol use disorders.

Conditions
Alcohol Abuse
Being tested
questionnaire
Medical subject headings
Alcoholism

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • questionnaireOther

    Completion of the questionnaire by the patient after consultation with the practitioner.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Alcohol marketing strategies

    Confirmation of alcohol marketing strategies significantly influencing alcohol risk perception alcohol cravings in patients with moderate to severe alcohol use disordersin a large population of people with alcohol use disorders seeking care.

    Measured: 1 day

Secondary outcomes (6)

  1. Alcohol craving

    Self-assessment of craving measured by a visual analog scale from 0 (no craving for alcohol) to 10 (irrepressible craving for alcohol) relative to the question "How much do you estimate your craving for alcohol? "

    Measured: 1 day

  2. Alcohol consumption

    Ability to control one's drinking, as measured by a visual analog scale from 0 (no ability to control) to 10 (perceived total control over drinking) relative to the question "How much do you estimate your ability to control your own drinking?"

    Measured: Day 1

  3. Evaluation of severity of alcohol use disorders

    Severity of alcohol use disorders as measured by the number of DSM5 (Diagnostic and Statistical manual of Mental disorders 5) criteria. The DSM5 score is diagnosis of addiction is based on welldefined criteria set out in the Diagnostic and Statistical manual of Mental disorders (DSM), the fifth edition of which was published in 2013. The questionnaire consists of 11 items (diagnostic criteria for substance use disorders from the American Psychiatric Association's DSM V). The presence of 2 to 3 criteria: low addiction / Presence of 4 to 5 criteria : moderate addiction / Presence of 6 or more criteria: severe addiction.

    Measured: Day 1

  4. Evaluation of severity of alcohol use disorders

    Severity of alcohol use disorders as measured will be evaluated by Alcohol Use Disorders Identification Test (AUDIT) scale. AUDIT is a 10-item screening tool to assess alcohol consumption, drinking behaviors, and alcohol-related problems. A score of 8 or more is considered to indicate hazardous or harmful alcohol use.

    Measured: Day 1

  5. Socio-demographic characteristics

    The impact of marketing stimuli will be evaluated according to socio-demographic characteristics.

    Measured: Day 1

  6. Alcohol consumption

    Assessment of the type of alcohol consumption

    Measured: Day1

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Nov 2021
  2. Study start7 Feb 2022
  3. Primary completion7 Dec 2023
  4. Study completion7 Dec 2023

Why it stopped: Recruitment difficulties

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
287 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05125783
Sponsor's protocol ID
29BRC21.0178
Acronym
DEPREV_Phase_2
Status last verified
Mar 2024
First submitted
8 Nov 2021
Last updated
6 Feb 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: All collected data that underlie results in a publication.

Questions about this trial

What is this clinical trial studying?

An observational study of Alcohol Abuse, run by University Hospital, Brest at 7 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 6 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 7 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: Recruitment difficulties). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Alcohol marketing strategies (time frame: 1 day). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05125783.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Feb 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in